STUDY OBJECTIVE: To describe the changes in serum alanine aminotransferase (ALT) levels in nondrinkers receiving acetaminophen for 10 days. DESIGN: Prospective, open-label study. SETTING: Outpatient clinical research center. PATIENTS: Twenty-four healthy volunteers who reported an average alcohol consumption of less than one drink/day for the 30 days preceding study enrollment. INTERVENTION: Patients were administered acetaminophen 4 g/day for 10 days (study days 1-10). MEASUREMENTS AND MAIN RESULTS: Serum ALT level, total bilirubin level, and international normalized ratio (INR) were measured on study days 0, 4, 7, 9, 11, and 14. Median ALT level increased from 24 U/L on day 0 to 39 U/L on day 7, and remained elevated through day 11 (39 U/L); these increases were statistically significant (p=0.0002). Median ALT level began to trend down by day 14 (35 U/L). Fourteen subjects (58%) had ALT levels above the upper limit of normal; the largest elevation was 3.8 times the upper limit of normal (day 7). No increases in INR or total bilirubin level were noted during the study, and no subject developed symptoms of liver injury (e.g., abdominal pain, jaundice). CONCLUSION: Daily use of acetaminophen at the maximum dose of 4 g/day for 10 days caused asymptomatic ALT level elevations in subjects who do not consume alcohol. The clinical implication of these elevations remains unclear. Future studies should evaluate ALT changes and their clinical effects when acetaminophen is given for long periods of time.
STUDY OBJECTIVE: To describe the changes in serum alanine aminotransferase (ALT) levels in nondrinkers receiving acetaminophen for 10 days. DESIGN: Prospective, open-label study. SETTING:Outpatient clinical research center. PATIENTS: Twenty-four healthy volunteers who reported an average alcohol consumption of less than one drink/day for the 30 days preceding study enrollment. INTERVENTION: Patients were administered acetaminophen 4 g/day for 10 days (study days 1-10). MEASUREMENTS AND MAIN RESULTS: Serum ALT level, total bilirubin level, and international normalized ratio (INR) were measured on study days 0, 4, 7, 9, 11, and 14. Median ALT level increased from 24 U/L on day 0 to 39 U/L on day 7, and remained elevated through day 11 (39 U/L); these increases were statistically significant (p=0.0002). Median ALT level began to trend down by day 14 (35 U/L). Fourteen subjects (58%) had ALT levels above the upper limit of normal; the largest elevation was 3.8 times the upper limit of normal (day 7). No increases in INR or total bilirubin level were noted during the study, and no subject developed symptoms of liver injury (e.g., abdominal pain, jaundice). CONCLUSION: Daily use of acetaminophen at the maximum dose of 4 g/day for 10 days caused asymptomatic ALT level elevations in subjects who do not consume alcohol. The clinical implication of these elevations remains unclear. Future studies should evaluate ALT changes and their clinical effects when acetaminophen is given for long periods of time.
Authors: Paul B Watkins; Neil Kaplowitz; John T Slattery; Connie R Colonese; Salvatore V Colucci; Paul W Stewart; Stephen C Harris Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: Edwin K Kuffner; Anthony R Temple; Kimberly M Cooper; Jeffrey S Baggish; Dennis L Parenti Journal: Curr Med Res Opin Date: 2006-11 Impact factor: 2.580
Authors: E K Kuffner; J L Green; G M Bogdan; P C Knox; R B Palmer; K Heard; J T Slattery; R C Dart Journal: BMC Med Date: 2007-05-30 Impact factor: 8.775
Authors: Barry Rumack; Kennon Heard; Jody Green; Donald Albert; Becki Bucher-Bartelson; Michael Bodmer; Marco L A Sivilotti; Richard C Dart Journal: Pharmacotherapy Date: 2012-07-31 Impact factor: 4.705
Authors: Kennon J Heard; Jody L Green; Laura P James; Bryan S Judge; Liza Zolot; Sean Rhyee; Richard C Dart Journal: BMC Gastroenterol Date: 2011-03-14 Impact factor: 3.067